They summarized various variables (molecular classes, tumour mutational burden, mutational signatures, cell-free DNA (ctDNA), PD-L1, patient’s characteristics, concomitant medications, inflammatory indices, combined tools, and radiomic-based modes) and evaluated their strength of evidence and clinically meaningfulness. The gene discussed is CD274; the disease is neoplasm.